10-Q: Oramed Pharmaceuticals Reports Strong Q1 2026 Results Driven by Investments

Oramed Pharmaceuticals Inc. reported a significant net income of $38.3 million for Q1 2026, a substantial turnaround from a net loss in the prior year, primarily driven by substantial gains from its investment portfolio.

Summary

• Oramed Pharmaceuticals Inc. reported a net income of $38.3 million for the first quarter ended March 31, 2026, a significant improvement from a net loss of $7.6 million in the same period of 2025.
• The company's financial performance was largely influenced by substantial gains from its investment revaluations, particularly in Alpha Tau and Scilex.
• Revenues for the quarter were nil, compared to $2 million in Q1 2025, which was related to a technology license agreement.
• Research and development expenses decreased by 28% to $1.6 million, while general and administrative expenses decreased by 10% to $2.1 million.
• The company ended the quarter with $13.2 million in cash and cash equivalents, and a working capital surplus of $58.6 million.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report due to the significant turnaround in net income driven by investment gains, despite the lack of operational revenue. The strategic shift and successful investment revaluations are key highlights.

Positives

• Achieved a net income of $38.3 million in Q1 2026, a significant turnaround from a net loss of $7.6 million in Q1 2025.
• Total assets increased to $268.8 million as of March 31, 2026, from $230.9 million as of December 31, 2025.
• Stockholders' equity increased to $238.3 million as of March 31, 2026, from $199.7 million as of December 31, 2025.
• Significant financial income of $44.8 million was generated, primarily from investment revaluations.
• Operating loss decreased by 30% to $3.7 million from $4.5 million in the prior year's quarter.
• Working capital surplus of $58.6 million as of March 31, 2026.

Negatives

• Revenues were $0 for the quarter, compared to $2 million in the prior year's quarter.
• The company has incurred cumulative losses of approximately $85.1 million since inception.
• Cash and cash equivalents decreased significantly to $13.2 million from $45.9 million at the end of the previous year.
• Investing activities used $19.5 million in cash during the quarter.
• Financing activities used $10.4 million for dividend payments.

Risks

• The company expects to increase research and development activities and related expenses for the revised Phase 3 trial through OraTech.
• Additional financing may not be available on acceptable terms, or at all, due to difficult capital markets, which could force the company to reduce operations or divest assets.
• The company is subject to foreign currency exchange rate fluctuations, primarily related to the Israeli New Shekel.
• Investments in real estate involve significant risks and may not provide long-term value appreciation or expected income streams.
• The company's loan agreements in real estate projects expose it to potential market, liquidity, and execution risks.
• The company's exposure to potential litigation remains a risk.
• The company may not realize a return on its investments in marketable securities.
• Risks related to the investment in Ruby Capital Investment Fund Sapphire II, including illiquidity, capital call obligations, uncertainty regarding returns, and potential loss of invested capital.
• The political and military situation in Israel remains volatile and could impact operations.
• The company's ability to recover proceeds and/or collateral under the Tranche A Note and Tranche B Note from Scilex is subject to risks.
• The fluctuating market price and liquidity of the common stock of Scilex, Alpha Tau, and Lifeward underlying the warrants the company holds.

Future Outlook

The company expects to increase research and development activities and related expenses for the revised Phase 3 trial through OraTech. However, it acknowledges the need for additional financing and the potential difficulty in securing it, which could necessitate operational reductions or asset divestitures. Despite these challenges, based on current cash resources and commitments, the company believes it can maintain planned activities and expenditures for at least the next 12 months.

Management Comments

• Oramed has evolved into a strategic operator of medical technology businesses, acquiring controlling interests and actively managing portfolio companies.
• The company's value creation derives from operating these businesses, not from holding securities for investment purposes.
• The Lifeward transaction aligns the company with a revenue-generating medical robotics business, providing near-term cash flow and diversified exposure.
• The company believes Lifeward is well-positioned to realize the value of its product platform with a new strategic direction and leadership team.
• The transfer of the POD platform to Lifeward is expected to deliver long-term upside, alongside the near-term contribution of Lifeward's commercial portfolio, driving growth and shareholder value.

Industry Context

StockSavvy.ai notes that Oramed's strategic shift towards operating medical technology businesses, rather than solely holding securities, reflects a broader trend in the biotech and pharma investment landscape. This approach aims to unlock value through active management and operational integration, as seen in the Lifeward transaction, which combines Oramed's POD technology with Lifeward's established robotics and rehabilitation solutions.

Comparison to Industry Standards

• The significant net income of $38.3 million in Q1 2026, driven by investment gains, is a notable positive for Oramed, especially when compared to its net loss of $7.6 million in Q1 2025. This turnaround highlights the impact of strategic investment revaluations.
• The company's R&D expenses decreased by 28% year-over-year, which could be viewed cautiously in the context of ongoing clinical trials, though it may also reflect a strategic reallocation of resources or a shift in focus post-Lifeward transaction.
• The substantial financial income of $44.8 million, largely from investment revaluations, significantly boosted the bottom line. This contrasts with many early-stage biotech companies that are heavily reliant on operational revenue and R&D breakthroughs for financial performance.

Legal Proceedings

• From time to time, the company may become involved in legal proceedings or be subject to claims arising in the ordinary course of business.

Related Party Transactions

• Consulting agreement with KNRY Ltd. (owned by Chief Scientific Officer) for services as Chief Scientific Officer.
• Employment agreement with the Chief Scientific Officer for services as Chief Scientific Officer of the Subsidiary.
• Consulting agreement with Shnida Ltd. (owned by President and CEO) for services as President and Chief Executive Officer.
• Employment agreement with the President and Chief Executive Officer for services as President and Chief Executive Officer of the Subsidiary.

Stakeholder Impact

• Shareholders: The significant net income and increase in equity are positive for shareholders. However, the reliance on investment gains and the need for future financing introduce potential risks.
• Employees: The company's strategic shift and ongoing R&D activities suggest continued employment opportunities, though future financing needs could impact operations.
• Creditors: The company's working capital surplus and cash position provide some comfort, but the cumulative losses and reliance on external financing are factors for creditors to consider.

Next Steps

• Continue to increase research and development activities and related expenses for the revised Phase 3 trial through OraTech.
• Seek additional financing as needed.
• Manage the clinical study of OraTech Ltd.'s investigational oral insulin capsule product through completion.
• Monitor the volatile geopolitical situation in Israel and its potential impact on operations.
• Continue to manage and optimize the company's portfolio of medical technology businesses.

Key Dates

Recommendation

The company has demonstrated a significant improvement in its financial results, primarily driven by strong investment gains, leading to a substantial net income. However, the lack of operational revenue, ongoing cumulative losses, and the acknowledged need for future financing in a challenging capital market environment warrant a cautious approach. The strategic shift towards operating medical technology businesses is promising but requires time to demonstrate sustainable operational profitability. Therefore, a 'hold' recommendation is appropriate, pending further evidence of consistent operational performance and successful capital raising.

Keywords

Oramed Pharmaceuticals, Form 10-Q, Quarterly Report, Financial Statements, Investment, Alpha Tau, Lifeward, Scilex, Net Income, Loss, Research and Development, Cash Flow